BRPI0818268A2 - antígenos de vacina humana derivados de cloroplasto contra a malária - Google Patents

antígenos de vacina humana derivados de cloroplasto contra a malária

Info

Publication number
BRPI0818268A2
BRPI0818268A2 BRPI0818268A BRPI0818268A BRPI0818268A2 BR PI0818268 A2 BRPI0818268 A2 BR PI0818268A2 BR PI0818268 A BRPI0818268 A BR PI0818268A BR PI0818268 A BRPI0818268 A BR PI0818268A BR PI0818268 A2 BRPI0818268 A2 BR PI0818268A2
Authority
BR
Brazil
Prior art keywords
chloroplast
vaccine antigens
derived human
against malaria
antigens against
Prior art date
Application number
BRPI0818268A
Other languages
English (en)
Inventor
Henry Daniel
Chakrabarti Debopam
Original Assignee
Univ Central Florida Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Central Florida Res Found Inc filed Critical Univ Central Florida Res Found Inc
Publication of BRPI0818268A2 publication Critical patent/BRPI0818268A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0818268A 2007-10-31 2008-10-31 antígenos de vacina humana derivados de cloroplasto contra a malária BRPI0818268A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98411107P 2007-10-31 2007-10-31
US5744208P 2008-05-30 2008-05-30
US9145808P 2008-08-25 2008-08-25
PCT/US2008/012361 WO2009058355A2 (en) 2007-10-31 2008-10-31 Chloroplast-derived human vaccine antigens against malaria

Publications (1)

Publication Number Publication Date
BRPI0818268A2 true BRPI0818268A2 (pt) 2017-05-09

Family

ID=40591699

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818268A BRPI0818268A2 (pt) 2007-10-31 2008-10-31 antígenos de vacina humana derivados de cloroplasto contra a malária

Country Status (4)

Country Link
US (1) US20090297550A1 (pt)
CN (1) CN101951951A (pt)
BR (1) BRPI0818268A2 (pt)
WO (1) WO2009058355A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594956A4 (en) 2003-02-03 2007-08-01 Fraunhofer Usa Inc SYSTEM FOR EXPRESSION OF GENES IN PLANTS
CA2526720C (en) 2003-05-22 2013-10-22 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
EP1919504B1 (en) 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
US20100266640A1 (en) * 2009-04-20 2010-10-21 Henry Daniell Plant-Derived Cholera and Malaria Vaccine
US10689633B2 (en) 2008-02-29 2020-06-23 The Trustees Of The University Of Pennsylvania Expression of β-mannanase in chloroplasts and its utilization in lignocellulosic woody biomass hydrolysis
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
WO2010037063A2 (en) * 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Plasmodium vaccines, antigens, compositions and methods
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US9724400B2 (en) 2009-11-09 2017-08-08 The Trustees Of The University Of Pennsylvania Administration of plant expressed oral tolerance agents
US10865419B2 (en) * 2011-10-24 2020-12-15 The Trustees Of The University Of Pennsylvania Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes
CN114106206B (zh) * 2021-12-02 2023-02-28 猎境(嘉兴)生物科技有限公司 一种利用植物膜系统生产重组疫苗的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030204864A1 (en) * 2001-02-28 2003-10-30 Henry Daniell Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
CN1330718A (zh) * 1998-10-07 2002-01-09 辛根塔参与股份公司 植物中的治疗活性蛋白质
US7037681B2 (en) * 2000-02-08 2006-05-02 University Of Hawaii Plasmodium falciparum merozoite surface protein-1 malaria produced in transgenic plants
US7029685B2 (en) * 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
WO2003057834A2 (en) * 2001-12-26 2003-07-17 University Of Central Florida Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines
WO2005032457A2 (en) * 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants

Also Published As

Publication number Publication date
WO2009058355A3 (en) 2009-06-18
US20090297550A1 (en) 2009-12-03
CN101951951A (zh) 2011-01-19
WO2009058355A2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
BRPI0818268A2 (pt) antígenos de vacina humana derivados de cloroplasto contra a malária
BRPI1009454A2 (pt) vacinas contra o câncer direcionadas a células apresentadoras de antígenos
DK2114993T3 (da) Vaccine
IL200859A0 (en) Oil-in-water emulsion influenza vaccine
ATE450271T1 (de) Impfstoff
DK2043682T3 (da) Influenzavaccine
IL211184B (en) Multivalent vaccine
IL201782A0 (en) Vaccine
BRPI0923006A2 (pt) vacinas meningococicas incluindo receptor de hemoglobina
GB0717911D0 (en) Vaccine
GB0700135D0 (en) Vaccine
GB0711858D0 (en) Vaccine
BRPI1014867A2 (pt) anticorpos contra a tweak humana e usos dos mesmos.
NO20100811A (no) Subenhetsvaksine for akvakutur
BRPI0916732A2 (pt) vacina contra hpv
BRPI0921578A2 (pt) vacinas unitemporais
BRPI0915605A2 (pt) Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo
EP2368899B8 (en) Avian influenza vaccine
GB0710538D0 (en) Vaccine
DK2175881T3 (da) Intradermal influenzavaccine
EP2337847A4 (en) ADJUVANTS FOR VACCINES
BRPI0918719A2 (pt) vacina contra nematódeos
EP2331119A4 (en) MALARIA VACCINE
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0711357D0 (en) Vaccine

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]